Neurotrophic Keratitis Clinical Trials

Find Neurotrophic Keratitis Clinical Trials Near You

A Multicenter, Randomized, Vehicle-Controlled, Double-Masked to Open-Label Study to Evaluate the Safety and Efficacy of Lacripep 4 μM Ophthalmic Solution in Subjects With Neurotrophic Keratitis

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other, Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Objective: To evaluate the safety of Lacripep 4 μM Ophthalmic Solution and its effect on the ocular surface, visual function, corneal sensitivity, and quality of life of subjects with Stage 1 NK.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ Subjects who meet all the following inclusion criteria at Visit 1 (Screening) will be eligible to participate in the study.

• Are ≥18 years of age.

• Provide informed consent before any study-related procedures are performed.

• Are willing and able to comply with study procedures and the study schedule.

• Female subjects must either be incapable of pregnancy or must use an effective method of birth control for the duration of the study. Female subjects of childbearing potential must have a negative pregnancy test and not be nursing.

• Have all of the following in at least one eye:

‣ Stage 1 NK as defined by:

• Grade 3 cCFS using the National Eye Institute (NEI) scale (0-3 in one-point increments).

∙ Corneal sensitivity ≤4 cm in the central zone, as measured by Cochet-Bonnet aesthesiometer.

⁃ BCDVA +0.2 to +1.0 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent 20/32 to 20/200).

⁃ IOP ≤21 mmHg.

Locations
United States
Florida
University of South Florida
RECRUITING
Tampa
Indiana
Midwest Cornea Associates
RECRUITING
Carmel
Massachusetts
Eye Health Vision Center
RECRUITING
Russells Mills
Minnesota
Minnesota Eye Consultants
RECRUITING
Minneapolis
Missouri
Ophthalmology Associates
NOT_YET_RECRUITING
St Louis
New York
NYU Langone Center
RECRUITING
New York
Contact Information
Primary
Marc Odrich, MD
modrich@tearsolutions.com
646.249.2800
Backup
Michelle Carpenter
mcarpenter@rpspharma.com
Time Frame
Start Date: 2026-02-19
Estimated Completion Date: 2027-03
Participants
Target number of participants: 54
Treatments
Experimental: Lacripep
Placebo_comparator: Vehicle
Sponsors
Leads: TearSolutions, Inc.

This content was sourced from clinicaltrials.gov